GenEdit, a genetic pharmaceutical firm utilizing the 'NanoGalaxy Platform,' has entered into a strategic partnership with Genentech, a prominent global pharmaceutical company within the Roche Group. The collaboration focuses on the development of nano particles for gene therapy targeting autoimmune diseases. GenEdit is set to receive an initial payment of $15 million and could potentially earn up to $629 million in milestone payments, accompanied by additional royalties based on net sales upon commercialization.

Under this licensing agreement, the two companies will jointly work on advancing gene therapy for autoimmune diseases using GenEdit's NanoGalaxy Platform. The primary objective of the collaboration is the creation of soluble nano particles tailored for autoimmune conditions. Genentech will take charge of overseeing the pre-clinical and clinical development, approval processes, and the eventual commercialization of the therapy resulting from this joint research initiative.

Dr. Keun-Woo Lee, CEO of GenEdit, expressed, "We have entered into a contract with Genentech, a leading force in developing innovative treatment models, to pioneer a new therapeutic agent for autoimmune disease treatment." He added, "Through this collaboration, we anticipate showcasing the value and adaptability of GenEdit's NanoGalaxy Platform, which employs soluble nano particle technology in gene therapy delivery."

James Sabry, Global Head of Partnering at Roche Pharma, shared his perspective, stating, "We are actively seeking external innovation to complement our internal research efforts in advancing groundbreaking treatments for individuals grappling with autoimmune diseases." He further explained, "Through this agreement, we aim to harness the potential of GenEdit's polymer nano particle library platform, which has the capability to redefine the treatment landscape for challenging autoimmune conditions, providing much-needed relief."

Headquartered in San Francisco, USA, GenEdit specializes in the development of gene therapies utilizing its proprietary technology enabling intracellular gene delivery. Established in 2016 by Dr. Keun-Woo Lee, a Ph.D. in Biotechnology from UC Berkeley, who serves as the CEO, and Senior Vice President Hyo-Min Park.

GenEdit's in-house developed NanoGalaxy Platform features non-viral, non-lipid, and water-soluble nano particles. A company spokesperson highlighted its ability to selectively deliver various gene therapy substances to tissues with minimal immune response, allowing for re-administration and facilitating streamlined manufacturing. The spokesperson also emphasized that GenEdit is actively advancing in the development of therapies through its in-house pipeline and various partner programs, utilizing the NanoGalaxy Platform.